Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Gyre Therapeutics, Inc. (GYRE : NSDQ)

• Company Description    Gyre Therapeutics Inc. is a biotechnology company. It focused on organ fibrosis and inflammatory diseases. The company's product pipeline primarily includes F573, F528 and F230. Gyre Therapeutics Inc., formerly known as Catalyst Biosciences Inc., is based in United States. Number of Employees: 579

• Price / Volume Information    Yesterday's Closing Price: $7.06 Daily Weekly Monthly 20 Day Moving Average: 87,445 shares Shares Outstanding: 96.33 (millions) Market Capitalization: $680.11 (millions) Beta: 1.99 52 Week High: $13.75 52 Week Low: $6.11 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.63% -10.48% 12 Week -1.26% -2.85% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12770 HIGH BLUFF DRIVE SUITE 150 - SAN DIEGO,CA 92130 USA ph: 858-567-7770 fax: 336-480-2107 david.zhang@gyretx.com http://www.gyretx.com

• General Corporate Information    Officers Han Ying - Chief Executive Officer and Director Songjiang Ma - President and Director Ruoyu Chen - Chief Financial Officer Thomas Eastling - Director Gordon Carmichael - Director Peer Information Gyre Therapeutics, Inc. (CORR.) Gyre Therapeutics, Inc. (RSPI) Gyre Therapeutics, Inc. (CGXP) Gyre Therapeutics, Inc. (BGEN) Gyre Therapeutics, Inc. (GTBP) Gyre Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 403783103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/16/26 Share - Related Items Shares Outstanding: 96.33 Most Recent Split Date: 10.00 (0.07:1) Beta: 1.99 Market Capitalization: $680.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.27 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/16/26

• Fundamental Ratios P/E Current FY Estimate: 26.15 Trailing 12 Months: 88.25 PEG Ratio: - Price Ratios Price/Book: 4.95 Price/Cash Flow: 35.75 Price / Sales: 6.34 EPS Growth vs. Year Ago Period: 150.00% vs. Previous Quarter: 150.00% Sales Growth vs. Year Ago Period: 19.92% vs. Previous Quarter: 14.17% ROE 12/31/25 - - 09/30/25 - 9.50 06/30/25 - 7.67 ROA 12/31/25 - - 09/30/25 - 7.87 06/30/25 - 6.19 Current Ratio 12/31/25 - - 09/30/25 - 6.19 06/30/25 - 5.40 Quick Ratio 12/31/25 - - 09/30/25 - 5.64 06/30/25 - 4.87 Operating Margin 12/31/25 - - 09/30/25 - 10.40 06/30/25 - 8.08 Net Margin 12/31/25 - - 09/30/25 - 6.20 06/30/25 - 4.08 Pre-Tax Margin 12/31/25 - - 09/30/25 - 14.24 06/30/25 - 11.33 Book Value 12/31/25 - - 09/30/25 - 1.43 06/30/25 - 1.38 Inventory Turnover 12/31/25 - - 09/30/25 - 0.61 06/30/25 - 0.57 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©